JP2024540537A5 - - Google Patents

Info

Publication number
JP2024540537A5
JP2024540537A5 JP2024529579A JP2024529579A JP2024540537A5 JP 2024540537 A5 JP2024540537 A5 JP 2024540537A5 JP 2024529579 A JP2024529579 A JP 2024529579A JP 2024529579 A JP2024529579 A JP 2024529579A JP 2024540537 A5 JP2024540537 A5 JP 2024540537A5
Authority
JP
Japan
Application number
JP2024529579A
Other languages
Japanese (ja)
Other versions
JP2024540537A (ja
JPWO2023092057A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/080113 external-priority patent/WO2023092057A1/en
Publication of JP2024540537A publication Critical patent/JP2024540537A/ja
Publication of JPWO2023092057A5 publication Critical patent/JPWO2023092057A5/ja
Publication of JP2024540537A5 publication Critical patent/JP2024540537A5/ja
Pending legal-status Critical Current

Links

JP2024529579A 2021-11-18 2022-11-18 プログラニュリン発現を調節するための化合物及び方法 Pending JP2024540537A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163281057P 2021-11-18 2021-11-18
US63/281,057 2021-11-18
PCT/US2022/080113 WO2023092057A1 (en) 2021-11-18 2022-11-18 Compounds and methods for modulating progranulin expression

Publications (3)

Publication Number Publication Date
JP2024540537A JP2024540537A (ja) 2024-10-31
JPWO2023092057A5 JPWO2023092057A5 (https=) 2025-11-06
JP2024540537A5 true JP2024540537A5 (https=) 2025-11-06

Family

ID=86397858

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024529579A Pending JP2024540537A (ja) 2021-11-18 2022-11-18 プログラニュリン発現を調節するための化合物及び方法

Country Status (4)

Country Link
US (1) US20250109396A1 (https=)
EP (1) EP4433591A1 (https=)
JP (1) JP2024540537A (https=)
WO (1) WO2023092057A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260051070A (ko) 2023-08-10 2026-04-15 하네스 테라퓨틱스 리미티드 기능적 핵산
WO2025104638A1 (en) * 2023-11-17 2025-05-22 Universita' Degli Studi Di Brescia Antisense oligonucleotides for modulation of progranulin splicing
GB202401412D0 (en) 2024-02-02 2024-03-20 Harness Therapeutics Ltd Functional nucleic acid

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2520935A3 (en) * 2006-08-09 2013-02-13 Homestead Clinical Corporation Organ-specific proteins and methods of their use
CN106967799A (zh) * 2017-03-24 2017-07-21 杭州艾迪康医学检验中心有限公司 检测btk基因突变的方法、寡核苷酸及其应用
US12595479B2 (en) * 2019-03-20 2026-04-07 President And Fellows Of Harvard College Antisense oligonucleotide-based progranulin augmentation therapy in neurodegenerative diseases
TW202208628A (zh) * 2020-05-13 2022-03-01 瑞士商赫孚孟拉羅股份公司 靶向顆粒蛋白前體之寡核苷酸促效劑

Similar Documents

Publication Publication Date Title
JP2024540537A5 (https=)
BR102022023461A2 (https=)
BY13175U (https=)
CN307045347S (https=)
CN307047954S (https=)
CN307047707S (https=)
CN307047586S (https=)
CN307047013S (https=)
BY13161U (https=)
CN307045698S (https=)
CN307045559S (https=)
BY13170U (https=)
BY13158U (https=)
CN307045224S (https=)
CN307045016S (https=)
CN307044833S (https=)
CN307044822S (https=)
CN307044361S (https=)
CN307016005S8 (https=)
BY23966C1 (https=)
BY23965C1 (https=)
BY23963C1 (https=)
BY13176U (https=)
BY13159U (https=)
CN307049398S (https=)